Hi Disc,
Would not be surprising to see Actavis make a move on QRX post FDA approval IR.
The CR market is twice the IR market and CITI are calling QRX to be profitable FY 13.
Oxy goes generic 2013 so with the QRX product being 12 hour release and less side effects the market is ripe for the picking.
Regards,
big xt, page-49
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
